The Coalition to Stop Opioid Overdose (CSOO) is proud to announce A New PATH (Parents for Addiction Treatment and Healing) as a new member of the coalition. A New PATH works with families, individuals in recovery, healthcare professionals and community leaders to reduce the stigma associated with addictive illness through education and compassionate support and to advocate for therapeutic rather than punitive drug policies.

The Coalition to Stop Opioid Overdose (CSOO) enthusiastically welcomes Shatterproof as a new member of the Coalition. Shatterproof is a national nonprofit organization dedicated to ending the devastation addiction causes families.

The Coalition to Stop Opioid Overdose (CSOO) is thrilled to announce The Kennedy Forum as the newest member of the coalition. Founded by the Honorable Patrick J. Kennedy, The Kennedy Forum seeks to set a new standard for the future of health care in the United States which unites the health care system and rallies the mental health community.

Patients struggling with opioid addiction often live in rural areas where there are few to no providers who can prescribe medications that are controlled substances as part of a treatment plan to treat addiction. The growth in the use of telemedicine represents a remarkable opportunity to use new technologies to care for those who lack access to transportation or endure other geographical barriers.

Washington, DC – ACOG, AAP, ASAM, March of Dimes and NOFAS released a statement in response to the policy instituted by the Big Horn County Attorney’s Office in Montana to prosecute and incarcerate pregnant women for drug/alcohol use.

The opioid epidemic continued throughout the United States in 2017. State legislatures have remained engaged on this issue, with every state enacting some type of measure supporting prevention, treatment, or recovery in the past two years.

Several weeks ago, ASAM contacted the CDC to discuss the persistence of misunderstandings surrounding dosage thresholds in the CDC Guidelines for Prescribing Opioids for Chronic Pain – 2016 (Guideline) and addiction medicine.

On December 30, 2017, the Food and Drug Administration (FDA) announced the approval of Sublocade, a monthly formulation of buprenorphine subcutaneous injection for treatment of opioid dependence. This injection is the first monthly formulation of buprenorphine to be approved by the FDA.